Inicio
Explorar
nav.journalClub
Tendencias
Más
Synapse
⌘+K
Synapse
Idioma
Español
Español
Table 2 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit | Synapse
September 16, 2025
Open Access
Ver artículo completo
Table 2 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit
CX
Camila Bragança Xavier
The University of Texas MD Anderson Cancer Center
CA
Clark R. Andersen
The University of Texas MD Anderson Cancer Center
JL
JoAnn Lim
The University of Texas MD Anderson Cancer Center
Ver todo
Puntos clave
The analysis shows how drug interactions affect treatment outcomes in patients with solid tumors, improving patient management.
Patients undergoing immunotherapy for solid tumors had varied responses based on identified drug interactions.
Using a drug interaction framework, the research draws upon data collected in a Phase I unit for improved outcomes in treatment.
The findings may inform future immunotherapy strategies, enabling better tailored treatments for solid tumor patients.
Resumen
Response data according to therapy type.
Preguntar a la IA
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Preguntar a la IA
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Cite This Study
Copy
Xavier et al. (Mon,) studied this question.
synapsesocial.com/papers/68d4508931b076d99fa5873e
https://doi.org/https://doi.org/10.1158/2767-9764.30126780